Description

Technical Parameters

Introduction

peptides

product-1400-1400

Products Description

# **Systematic analysis of CJC-1295 without DAC 5mg + IPA 5mg combination peptide**

## **1. Classification and overview**

### **1.1 Classification of peptide drugs**

CJC-1295 (without DAC) and IPA (ipamorelin) are both **synthetic peptide drugs**, belonging to the category of growth hormone releasing hormone (GHRH) analogs and growth hormone secretagogues (GHS).

- **CJC-1295 without DAC**: A modified GHRH analog that activates growth hormone (GH) secretion in the anterior pituitary.

- **IPA (ipamorelin)**: A synthetic growth hormone releasing peptide (GHRP) that stimulates GH release by binding to the growth hormone secretagogue receptor (GHS-R).

The combination of the two belongs to a **synergistically enhanced peptide formula**, which is designed to maximize GH pulse secretion through dual mechanisms (GHRH and GHS-R pathways).

## **2. Chemical structure and physicochemical properties**

### **2.1 Chemical properties of CJC-1295 without DAC**

- **Molecular formula**: C₁₆₅H₂₆₇N₄₉O₄₄

- **Molecular weight**: about 3367.8 Da

- **Structural features**:

- It consists of 30 amino acid residues and contains the core sequence of natural GHRH (1-29).

- It has no drug affinity complex (DAC) and has a short half-life (about 30 minutes to 1 hour).

- **Solubility**: It is easily soluble in water or weakly acidic buffer (pH 4.0-6.0). It is recommended to use sterile water for injection or normal saline for preparation.

- **Stability**: Need to be stored in a refrigerator (2-8°C) and avoid repeated freezing and thawing to prevent degradation.

### **2.2 Chemical properties of IPA (Ipamorelin)**

- **Molecular formula**: C₄₅H₅₅N₁₁O₆

- **Molecular weight**: Approximately 902.0 Da

- **Structural features**:

- A pentapeptide (5 amino acids) with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂.

- Contains non-natural amino acids (such as Aib, D-2-Nal) to enhance metabolic stability.

- **Solubility**: Easily soluble in water or weak alkaline solution (pH 7.0-8.0).

- **Stability**: Can be stored at -20°C for a long time in a dry state, and it is recommended to use it within 24 hours in a solution state.

### **2.3 Color and appearance**

- **CJC-1295 without DAC**: White or off-white freeze-dried powder in high purity state.

- **IPA**: Pure product is white crystalline powder.

- **After mixing**: The solution is colorless and transparent, without suspended particles or turbidity.

## **3. Pharmacological effects and synergistic advantages**

### **3.1 Mechanism of action**

- **CJC-1295 without DAC**:

- Binds to pituitary GHRH receptors, activates adenylate cyclase (AC) signaling pathway, promotes GH synthesis and pulsatile release.

- No DAC modification, avoids continuous secretion of GH, and reduces side effects (such as insulin resistance).

- **IPA**:

- Activates GHS-R1a receptors, enhances the activity of hypothalamic growth hormone-releasing hormone (GHRH), and indirectly promotes GH secretion by inhibiting somatostatin.

### **3.2 Synergistic effect**

- **Pulse GH secretion**: The combination of the two can simulate the natural GH pulse pattern (3-5 times a day) to avoid desensitization caused by continuous secretion.

- **Dose-dependent enhancement**: Experiments show that the combination of CJC-1295 + IPA can increase the GH peak by 3-5 times, which is better than single use.

## **4. Clinical application and indications**

### **4.1 Medical field**

- **Growth hormone deficiency (GHD)**: Used for replacement treatment of GHD in adults and children.

- **Anti-aging and metabolic regulation**: Improve muscle mass, bone density and skin elasticity through the GH-IGF-1 axis.

- **Postoperative recovery**: Accelerate wound healing and tissue repair.

### **4.2 Sports and fitness field**

- **Muscle gain and fat loss**: GH promotes protein synthesis and fat decomposition, suitable for athletes and bodybuilders.

- **Joint repair**: Improve joint health through IGF-1-mediated chondrocyte proliferation.

## **5. Advantages and limitations**

### **5.1 Advantages**

- **Half-life matching**: The half-life of CJC-1295 (without DAC) is similar to that of IPA, which is suitable for combined injection.

- **High safety**: The DAC-free design reduces the side effects associated with continuous GH secretion (such as edema, carpal tunnel syndrome).

- **Cost-effectiveness**: The 5mg dose is suitable for short-term and medium-term treatment, and its economy is better than long-acting preparations.

### **5.2 Limitations**

- **Frequent injections**: Due to the short half-life, 1-2 subcutaneous injections are required daily.

- **Individual differences**: GH secretion response may vary depending on age, gender and baseline GH level.

## **6. Safety and side effects**

- **Common side effects**: Redness and swelling at the injection site, transient headache, mild joint pain.

- **Serious risks**: Rare but need to be vigilant include hyperglycemia and thyroid dysfunction (long-term high-dose use).

- **Contraindications**: Contraindicated for patients with active tumors, during pregnancy, and those allergic to peptides.

## **7. Preparation and Usage Recommendations**

- **Recommended dose**: 5 mg each of CJC-1295 (without DAC) and IPA, once a day or in divided injections.

- **Preparation method**:

1. Reconstitute the lyophilized powder with 1-2 ml of sterile water for injection.

2. Slowly rotate and mix to avoid violent shaking that may cause peptide chain breakage.

- **Storage conditions**: Unopened lyophilized powder must be refrigerated away from light, and the reconstituted solution is recommended to be used within 24 hours.

## **8. Research progress and future directions**

- **Long-term improvement**: Develop sustained-release dosage forms (such as microspheres or nanocarriers) to reduce the frequency of injections.

- **Targeted delivery**: Enhance blood-brain barrier penetration by modifying the peptide chain and directly act on the hypothalamus.

- **Combination therapy**: Explore combined use with insulin sensitizers (such as metformin) to optimize metabolic benefits.

## **Conclusion**

The combination of CJC-1295 without DAC and IPA represents the forefront of peptide hormone therapy. Its dual mechanism of action, high safety, and adjustable pulsed secretion pattern make it have broad prospects in the fields of medicine and sports. However, further research is needed to optimize the dosing regimen and pay attention to the safety data of long-term use.